Filing Analysis
Rallybio Corp has entered into a Merger Agreement with Avenzo Therapeutics, Inc. effectively resulting in a reverse merger where Avenzo will become a subsidiary of Rallybio, but Avenzo's management will take over the combined company.
🚩 Red Flags
- Extreme dilution: Existing Rallybio shareholders are diluted from 100% to approximately 2.8% ownership.
- Reverse stock split: The filing explicitly mentions a reverse stock split as a stockholder matter to be approved.
- Complete management turnover: All current Rallybio officers and directors are expected to resign.
- Low valuation: Rallybio is valued at only $15.0 million relative to Avenzo's $300.0 million.
📋 Key Facts
- Merger Agreement signed May 31, 2026, between Rallybio and Avenzo Therapeutics.
- Avenzo's pre-merger equityholders are expected to own ~56.6% of the combined company, while Rallybio's pre-merger equityholders will own only ~2.8% on a fully diluted basis.
- Concurrent financing is expected to bring in $215.0 million in gross proceeds, with those investors owning ~40.6% of the combined company.
- Valuations used for the exchange ratio: Rallybio at $15.0 million and Avenzo at $300.0 million.
- Avenzo's management team (CEO Athena Countouriotis, CFO Scott Lipman, etc.) will lead the combined company; all current Rallybio executives and directors are expected to resign.
- The transaction includes a proposed reverse stock split of Rallybio common stock and a name change to 'Avenzo Therapeutics, Inc.'
- Rallybio will distribute its net cash to shareholders prior to closing.
Rallybio Corporation announced the termination of its merger agreement with Candid Therapeutics, Inc. after Candid entered into an alternative agreement with UCB S.A. Rallybio is entitled to receive a $50 million termination fee plus expense reimbursements as a result of the deal's collapse.
🚩 Red Flags
- Failure of a previously announced strategic merger and reorganization.
- Withdrawal of a registration statement (Form S-4) indicating a halt to the planned capital structure changes.
📋 Key Facts
- The Merger Agreement with Candid Therapeutics, originally dated March 1, 2026, was terminated on May 3, 2026.
- Candid Therapeutics terminated the deal to pursue a 'Permitted Alternative Agreement' with UCB S.A.
- Rallybio will receive a $50,000,000 Parent Termination Fee.
- Rallybio, Candid, and UCB entered into a Waiver on May 1, 2026, to facilitate the termination and release of claims.
- Rallybio intends to withdraw its Form S-4 registration statement previously filed for the merger.
Rallybio Corporation announced the immediate departure of its Chief Medical Officer, Steven Ryder, M.D., effective March 31, 2026. This departure occurs in the context of the company's pending merger with Candid Therapeutics, Inc., which was previously announced on March 1, 2026.
🚩 Red Flags
- Immediate departure of a key clinical executive (CMO) during a critical merger transition period.
📋 Key Facts
- Steven Ryder, M.D., served as Chief Medical Officer since January 2019.
- Departure is effective immediately as of March 31, 2026.
- Dr. Ryder will receive severance payments for termination 'without cause' as per his employment agreement.
- Upon closing of the merger with Candid Therapeutics, Dr. Ryder will receive enhanced 'change of control' severance benefits.
- Equity awards will remain outstanding and eligible to vest according to the Merger Agreement, exercisable for 90 days post-closing.
Rallybio Corp has entered into a definitive merger agreement with Candid Therapeutics in a reverse merger transaction that will result in Rallybio shareholders owning only 3.65% of the combined company. The deal includes a concurrent financing of approximately $505.5 million and will result in a complete change of management and a corporate name change to Candid Therapeutics, Inc.
🚩 Red Flags
- Extreme dilution for existing Rallybio shareholders (96.35% total dilution).
- Mandatory reverse stock split required to maintain listing and facilitate the merger.
- Total turnover of the executive team and board of directors.
- The transaction is heavily contingent on a large-scale concurrent financing ($200M minimum).
📋 Key Facts
- Rallybio equityholders will own approximately 3.65% of the combined company post-merger.
- Candid Therapeutics is valued at $750 million, while Rallybio is valued at $47.5 million (assuming $37.5 million in net cash).
- A concurrent financing is expected to raise $505.5 million, with a $200 million minimum required for closing.
- Ken Song, MD (Candid CEO) will become the CEO of the combined entity; all current Rallybio officers and directors will resign.
- The agreement necessitates a reverse stock split and a name change to 'Candid Therapeutics, Inc.'
- Candid may be required to pay a termination fee of up to $50 million under specific circumstances, while Rallybio's termination fee is $1.425 million.
Rallybio Corporation has announced a reverse stock split of its common stock at a ratio of 1-for-8, following stockholder approval on January 26, 2026. The split is scheduled to become effective at 12:01 a.m. ET on February 6, 2026.
🚩 Red Flags
- Reverse stock split: Often used to combat low share prices and avoid NASDAQ delisting requirements.
- Potential dilution/liquidity impact for retail shareholders.
📋 Key Facts
- Reverse stock split ratio set at 1-for-8.
- Effective date of the reverse split: February 6, 2026, at 12:01 a.m. ET.
- Stockholders approved an amendment to the Certificate of Incorporation via a Special Meeting on January 26, 2026.
- The ratio was selected within a previously approved range of 1-for-5 to 1-for-20.
- Post-split trading will begin under CUSIP number 75120L 209 on February 6, 2026.
Rallybio Corporation filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal notice of the press release containing these results.
📋 Key Facts
- Reporting date: November 6, 2025
- Period covered: Quarter ended September 30, 2025
- The company is an emerging growth company
- Financial results were issued via press release (Exhibit 99.1)
Rallybio Corp has failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the initial deadline of August 25, 2025. The company has been granted a 180-day extension until February 23, 2026, to restore compliance.
🚩 Red Flags
- Failure to meet minimum bid price requirement by initial deadline
- Explicit mention of a potential reverse stock split (often dilutive or signal of distress)
- Risk of delisting if compliance is not met by February 23, 2026
📋 Key Facts
- Company failed to meet the minimum $1.00 closing bid price requirement by the Initial Compliance Date of August 25, 2025.
- Nasdaq has granted a second compliance period lasting until February 23, 2026.
- The company's listing was transferred to the Nasdaq Capital Market on August 29, 2025.
- Management explicitly mentioned that a reverse stock split is being considered as a potential method to regain compliance.
Rallybio Corporation has filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- The company issued a press release on August 07, 2025, regarding financial results.
- Reporting period: Quarter ended June 30, 2025.
- The filing includes Exhibit 99.1 containing the earnings press release.
Rallybio Corporation entered into an agreement to sell 50% of its membership interests in RE Ventures I, LLC (the ENPP1 JV) to Recursion Pharmaceuticals, Inc. for a combination of cash and Recursion Class A Common Stock.
🚩 Red Flags
- Divestiture of a 50% stake in a joint venture may indicate a need for immediate liquidity or a strategic shift away from the specific asset/compound being developed by ENPP1 JV.
📋 Key Facts
- Sale date: July 8, 2025
- Transaction value: $7,500,000 in initial consideration (shares + potential cash adjustment)
- Consideration received: 1,457,952 shares of Recursion (RXRX) Class A Common Stock based on a VWAP of $5.1442
- Contingent consideration: Up to $12,500,000 in additional shares if specific milestones are met
- Ongoing revenue potential: Low single-digit royalties on annual net sales of products developed by the ENPP1 JV
- The ENPP1 JV is now an indirect wholly-owned subsidiary of Recursion Pharmaceuticals.
Rallybio Corporation entered into a new employment agreement with its Chief Medical Officer, Dr. Steven Ryder, effective June 25, 2025. The filing details his compensation structure, including base salary and performance-based bonuses, as well as severance terms.
🚩 Red Flags
- Significant severance obligations (1.5x salary + bonus for 18 months) in the event of a change in control.
📋 Key Facts
- Dr. Steven Ryder entered into a new employment agreement on June 25, 2025.
- Initial annual base salary is set at $531,227.
- Eligible for an annual target bonus of up to 40% of base salary based on performance goals.
- Agreement includes a one-year term with automatic successive one-year extensions unless notice is given.
- Severance terms include 12 months of base salary and COBRA coverage in the event of termination without cause or non-extension by the company.
Rallybio Corporation held its annual meeting of shareholders on May 13, 2025. The filing reports the election of two Class I directors and the ratification of Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual meeting held on May 13, 2025.
- Martin W. Mackay elected to the Board of Directors (Class I) with 23,833,701 votes in favor.
- Paula Soteropoulos elected to the Board of Directors (Class I) with 23,812,816 votes in favor.
- Shareholders ratified Deloitte and Touche LLP as independent registered public accounting firm for FY ending Dec 31, 2025.
Rallybio Corporation has filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal notice that a press release containing these results was issued on May 8, 2025.
📋 Key Facts
- The company announced quarterly financial results for the period ending March 31, 2025.
- The announcement was made via a press release issued on May 8, 2025.
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition).
Rallybio Corporation has announced the discontinuation of its RLYB212 program, intended for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The decision follows unfavorable pharmacokinetic data obtained from Phase 2 clinical trials.
🚩 Red Flags
- Failure of a clinical program in Phase 2 significantly impacts the company's pipeline value and future revenue potential.
📋 Key Facts
- Discontinuation of the RLYB212 program announced on April 8, 2025.
- The decision is based on pharmacokinetic data from a Phase 2 clinical trial.
- Target indication: prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Rallybio Corporation has amended its existing 'at-the-market' (ATM) sales agreement with TD Securities (USA) LLC, significantly reducing the maximum aggregate offering price. The cap on shares that can be sold under this agreement was lowered from $100 million to $9.55 million.
🚩 Red Flags
- Significant reduction (over 90%) in the maximum amount of capital that can be raised through this specific ATM facility suggests a strategic pivot or a response to market conditions/investor sentiment.
- The company is an 'emerging growth company,' which often correlates with higher cash burn rates and reliance on equity financing.
📋 Key Facts
- Amendment No. 1 to Sales Agreement dated March 13, 2025.
- Maximum aggregate offering price reduced from $100,000,000 to $9,550,000.
- TD Cowen (TD Securities) acts as the agent with a commission of up to 3.0% of gross proceeds.
- Sales are conducted via an 'at-the-market' offering under Form S-3 registration statement.
- As of the filing date, $0 in shares had been sold under this specific agreement.
Rallybio Corporation issued an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal mechanism to furnish the earnings press release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024.
- Filing date: March 13, 2025.
- The company is an 'Emerging Growth Company' as defined by the SEC.
- Financial results were released via press release (Exhibit 99.1).
Rallybio Corporation received a notification from Nasdaq stating that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until August 25, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5450(a)(1))
- Stock price has been below $1.00 for at least 30 consecutive business days, indicating significant downward momentum or lack of market interest.
📋 Key Facts
- Received notice on February 24, 2025, regarding a violation of Nasdaq Rule 5450(a)(1).
- The deficiency is based on the closing bid price being below $1.00 for the last 30 consecutive business days.
- Compliance deadline (Compliance Date) is August 25, 2025.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days before the Compliance Date.
- The company may be eligible for an additional 180-day period if it transfers to the Nasdaq Capital Market.
Rallybio Corporation filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 7, 2024.
📋 Key Facts
- Reporting period: Fiscal quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The company is an 'emerging growth company' as defined by the SEC.
- Financial results were released via press release (Exhibit 99.1).
Dr. Kush Parmar has announced his intention to resign from the Board of Directors and as Chair of the Nominating and Corporate Governance Committee, effective October 31, 2024.
📋 Key Facts
- Resignation date: Effective October 31, 2024.
- Roles departing: Member of the Board and Chair of the Nominating and Corporate Governance Committee.
- Reason for departure: The company explicitly stated the resignation is not due to any dispute or disagreement regarding operations, policies, or practices.
Rallybio Corporation filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release issued on August 8, 2024.
📋 Key Facts
- Report date: August 08, 2024
- Reporting period: Fiscal quarter ended June 30, 2024
- The company is an emerging growth company.
- Financial results were issued via press release (Exhibit 99.1).
Martin Mackay, Ph.D., will resign from his role as Executive Chairman and employee of Rallybio effective December 31, 2024. He will transition to a Board Chairman role and enter into a one-year consulting agreement starting January 1, 2025.
🚩 Red Flags
- Transition from executive/employee to consultant can sometimes mask underlying leadership instability or be used to manage exit costs.
- Change of Control clause accelerates equity vesting, which may create misalignment during M&A discussions.
📋 Key Facts
- Martin Mackay, Ph.D., is resigning as Executive Chairman and employee effective December 31, 2024.
- Dr. Mackay will remain on the Board of Directors and serve as Chairman of the Board post-employment.
- No severance will be paid for his resignation from employment.
- A consulting agreement is expected to begin January 1, 2025, lasting until at least January 1, 2026.
- The consulting fee is set at $18,750 per month, payable in arrears.
- Equity awards will continue to vest as a director; however, a Change of Control would trigger immediate vesting for outstanding awards as of Dec 31, 2024.
Rallybio Corporation held its annual meeting of shareholders on May 15, 2024. The filing reports the election of four Class III directors and the ratification of Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual meeting held on May 15, 2024.
- Four nominees elected to the Board of Directors (Wendy K. Chung, Robert Hopfner, Ronald Hunt, and Hui Liu) for terms expiring in 2027.
- Shareholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for FY ending Dec 31, 2024.
Rallybio Corporation filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Fiscal quarter ended March 31, 2024
- The company is an emerging growth company
- Financial results were issued via press release (Exhibit 99.1)
Rallybio Corp entered into a dual-track transaction with Johnson & Johnson (J&J) involving a collaboration agreement for FNAIT therapeutic solutions and a $6.6 million private placement of common stock to J&J Innovation – JJDC, Inc.
🚩 Red Flags
- The equity offering is an unregistered sale of common stock (Rule 506(c)), which will lead to dilution for existing shareholders.
- The company must register these shares within 120 days, creating a potential overhang on the stock price.
📋 Key Facts
- Entered into a Collaboration Agreement with Momenta Pharmaceuticals (a J&J subsidiary) on April 9, 2024, regarding FNAIT therapeutic solutions.
- Collaboration includes an upfront payment of $0.5 million and potential milestone payments totaling up to $3.7 million.
- Closed a private placement of 3,636,363 shares of common stock to J&J Innovation – JJDC, Inc. on April 10, 2024.
- The equity offering generated approximately $6.6 million in gross proceeds (before expenses).
- Includes a 180-day lock-up agreement for the purchaser of the new shares.
- Includes a registration rights agreement requiring RLYB to file a registration statement within 120 days.
Rallybio Corporation filed an 8-K to furnish its press release announcing financial results for the fiscal quarter and year ended December 31, 2023.
📋 Key Facts
- Report date: March 12, 2024
- Reporting period: Fiscal quarter and year ended December 31, 2023
- Company is an emerging growth company
- The information in Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Rallybio Corp announced a significant workforce reduction of approximately 45% of its positions to prioritize resources for clinical stage programs RLYB212 and RLYB116. The company expects to incur roughly $3.3 million in one-time severance and benefit charges, primarily recognized in Q1 2024.
🚩 Red Flags
- Significant workforce reduction (45% of staff) often indicates severe cash runway constraints or a major strategic retreat.
- Large one-time cash expenditure ($3.3M) in a micro-cap biotech context can impact liquidity significantly.
📋 Key Facts
- Workforce reduction involves approximately 45% of current positions.
- Estimated restructuring charges of ~$3.3 million (excluding share-based compensation).
- Charges are primarily cash-based severance and benefit payments.
- Expected recognition of substantially all charges in the quarter ending March 31, 2024.
- Strategic pivot to focus on Phase 2-ready programs: RLYB212 and RLYB116.